Stocktoria
Sol-Gel Technologies Ltd. SLGL
Sol-Gel Technologies Ltd. (SLGL) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $19.4M at a -31.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.695 |
| Retained earnings / assets | -7.922 |
| EBIT / assets | -0.252 |
| Equity / liabilities | 3.21 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SLGL | Sol-Gel Technologies Ltd. | 5/9 | -19.59 | — | +68% |
| SCYX | SCYNEXIS INC | 4/9 | -13.88 | — | — |
| ZYBT | Zhengye Biotechnology Holding Ltd | 4/9 | 1.49 | — | -91.1% |
| NAMS | NewAmsterdam Pharma Co N.V. | 2/9 | 8.19 | — | -50.6% |
| QURE | uniQure N.V. | 4/9 | -1.71 | — | -40.6% |
| NEUP | Neuphoria Therapeutics Inc. | 4/9 | -16.04 | — | — |
| CNTA | Centessa Pharmaceuticals plc | 4/9 | -1.11 | — | — |
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
FAQ
Is SLGL financially healthy?
Sol-Gel Technologies Ltd.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does SLGL pay a dividend?
No, Sol-Gel Technologies Ltd. does not currently pay a dividend.
How profitable is SLGL?
In FY2025, Sol-Gel Technologies Ltd. had a net margin of -31.6% and a return on equity of -26.9%.
What is the analyst price target for SLGL?
The average Wall-Street price target for Sol-Gel Technologies Ltd. is $193.00, about 169.9% above the recent price, from 3 analysts (consensus: strong buy).
Is SLGL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Sol-Gel Technologies Ltd.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.